Supplementary Figure 3 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma

Supplementary Figure 3 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma

<p>Changes of cell types based on (a) MCP-Counter and (b) Danaher module with post- vs pre-treatment samples. All tests were performed by non-parametric Wilcoxon test.</p>

Tallennettuna:

Bibliografiset tiedot
Päätekijä:	Tom Wei-Wu Chen (15053003) (author)
Muut tekijät:	Chia-Lang Hsu (11929719) (author), Ruey-Long Hong (15053006) (author), Jen-Chieh Lee (14954275) (author), Koping Chang (15053009) (author), Chih-Wei Yu (15053012) (author), San-Chi Chen (15050106) (author), Jhe-Cyuan Guo (15053015) (author), Mei-Lu Chen (15053018) (author), Meng-Chi Hsu (15053021) (author), Ting-Fang Kung (15053024) (author), Ann-Lii Cheng (15045786) (author), Chueh-Chuan Yen (15053027) (author)
Julkaistu:	2025
Aiheet:	Cancer Therapeutic Research and Development Clinical Research and Trials Clinical Trial Results Phase II clinical trials Sarcomas Soft-tissue sarcoma Translational Research
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia

Supplementary Figure 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Tekijä: Tom Wei-Wu Chen (15053003)
Julkaistu: (2025)

Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Tekijä: Tom Wei-Wu Chen (15053003)
Julkaistu: (2025)

Supplementary Figure 4 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Tekijä: Tom Wei-Wu Chen (15053003)
Julkaistu: (2025)

Supplementary Table 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Tekijä: Tom Wei-Wu Chen (15053003)
Julkaistu: (2025)

Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Tekijä: Srivandana Akshintala (16610490)
Julkaistu: (2025)

Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Tekijä: Srivandana Akshintala (16610490)
Julkaistu: (2025)

Supplementary Data 1 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis
Tekijä: Nam Q. Bui (14958210)
Julkaistu: (2025)

Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
Tekijä: John A. Ligon (15024477)
Julkaistu: (2025)

Supplementary Figure S1 from First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti–PD-L1 Antibody ZKAB001
Tekijä: Yan Zhou (15053225)
Julkaistu: (2025)

Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
Tekijä: Kristoffer Staal Rohrberg (15009138)
Julkaistu: (2025)

Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
Tekijä: Kristoffer Staal Rohrberg (15009138)
Julkaistu: (2025)

Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
Tekijä: Kristoffer Staal Rohrberg (15009138)
Julkaistu: (2025)

Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
Tekijä: Kristoffer Staal Rohrberg (15009138)
Julkaistu: (2025)

Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
Tekijä: Kristoffer Staal Rohrberg (15009138)
Julkaistu: (2025)

Table 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
Tekijä: Kristoffer Staal Rohrberg (15009138)
Julkaistu: (2025)

Table 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
Tekijä: Kristoffer Staal Rohrberg (15009138)
Julkaistu: (2025)

Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
Tekijä: Kristoffer Staal Rohrberg (15009138)
Julkaistu: (2025)

Table 4 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
Tekijä: Kristoffer Staal Rohrberg (15009138)
Julkaistu: (2025)

Supplementary Figure S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)
Tekijä: Roberto Carmagnani Pestana (15294422)
Julkaistu: (2025)

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
Tekijä: Ulka N. Vaishampayan (15051039)
Julkaistu: (2025)

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
Tekijä: Ulka N. Vaishampayan (15051039)
Julkaistu: (2025)

Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
Tekijä: Ulka N. Vaishampayan (15051039)
Julkaistu: (2025)

Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
Tekijä: Ulka N. Vaishampayan (15051039)
Julkaistu: (2025)

Supplementary Figure S1 from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)
Tekijä: Arathi Mohan (15561346)
Julkaistu: (2025)

Supplementary Table S4 from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)
Tekijä: Arathi Mohan (15561346)
Julkaistu: (2025)

Supplementary File 1 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Tekijä: Michael P. Ludwig (16721187)
Julkaistu: (2025)

Supplementary File 2 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Tekijä: Michael P. Ludwig (16721187)
Julkaistu: (2025)

Supplementary File 3 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Tekijä: Michael P. Ludwig (16721187)
Julkaistu: (2025)

Supplementary File 4 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Tekijä: Michael P. Ludwig (16721187)
Julkaistu: (2025)

Supplementary File 5 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Tekijä: Michael P. Ludwig (16721187)
Julkaistu: (2025)

Supplementary File 6 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Tekijä: Michael P. Ludwig (16721187)
Julkaistu: (2025)

Supplementary File 7 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Tekijä: Michael P. Ludwig (16721187)
Julkaistu: (2025)

Supplementary File 8 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Tekijä: Michael P. Ludwig (16721187)
Julkaistu: (2025)

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
Tekijä: Qingsheng Xu (17078830)
Julkaistu: (2025)

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
Tekijä: Qingsheng Xu (17078830)
Julkaistu: (2025)

Supplementary Tables 1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Tekijä: H. Josh Jang (15206898)
Julkaistu: (2025)

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Tekijä: Dwight H. Owen (15034782)
Julkaistu: (2025)

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Tekijä: Dwight H. Owen (15034782)
Julkaistu: (2025)

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Tekijä: Dwight H. Owen (15034782)
Julkaistu: (2025)

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Tekijä: Dwight H. Owen (15034782)
Julkaistu: (2025)

Cannot write session to /tmp/vufind_sessions/sess_vg5hnu6ti0c5oi8rb7lmlug50a